THE PSYCH SYMPOSIUM
With less than a month to go until The PSYCH Symposium at Prohibition Partners LIVE, there is only a limited amount of time to secure your place.
Join industry-leading figures and innovators working at the cutting edge of the psychedelic sector, November 17-20.
BUSINESS AND INVESTMENT
Pharmather partners with Arizona University to develop ketamine to treat Parkinson’s.
Revive Therapeutics signs psychedelic compound supply agreement with Havn Life.
Nova agrees to acquire psychedelic-focused autism research company Pilz BioScience.
Therapeutic psilocybin company Silo Pharma uplists to the OTCQB venture market.
NeuroPharm files a provisional patent for the treatment of PTSD with psilocybin.
Core One Labs signs letter of intent to acquire psilocybin API company Vocan.
Allied files US provisional patent for psilocybin-based therapeutics.
Numinus appoints leaders to its general advisory council, including Dennis McKenna.
Blackhawk acquires all outstanding shares of psychedelic company Trip Pharma.
Primo Nutraceuticals engages Medcan to conduct psilocybin chemo/genotyping studies.
THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION
Psilocybin is currently being studied as a treatment for a number of major public health conditions and early results have been promising, raising hope for medical practitioners around the world.
The Psychedelics as Medicine Report: Second Edition contains a comprehensive overview of the latest findings from the studies conducted so far as well the clinical trials currently taking place.
To fully understand the impact of psilocybin research, access the report, here.
REGULATION & LEGISLATION
RONAN LEVY OF FIELD TRIP HEALTH SPEAKS TO PSYCH
In our latest feature, we sit down with Ronan Levy, Executive Chairman of Field Trip Health, to speak about the recent public listing of his organisation as well as the future of the psychedelics industry.